Wall Street equity analysts tracking Agenus establish varying price targets that span dynamically based on upcoming clinical data readouts. Consensus forecasts and algorithmic predictions project potential target ranges moving upward from current trading levels, reflecting the high-risk, high-reward upside typical of clinical-stage oncology equities.